Twitter
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How Ozilia® is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Preferential issue of units 2025
  • FAQ
  • Svenska
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How Ozilia® is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Preferential issue of units 2025
  • FAQ
  • Svenska

Category: Uncategorized

  • Uncategorized

    Chordate Medical retains Swiss Advisor to initiate the exit process

  • Uncategorized

    Chordate Medical receives market authorization for the migraine indication in Saudi Arabia

  • Uncategorized

    Chordate Medical CEO presents the company and Ozilia at Aktieportföljen Live

  • Uncategorized

    Chordate participates in Feminvest’s investor conference in Stockholm on October 8th

  • Uncategorized

    US magazine Wired covers migraine and Chordate’s Ozilia treatment

  • Uncategorized

    Chordate Medical Receives First Order for Ozilia Migraine Treatment from Saudi Arabia

  • Uncategorized

    Kalqyl in updated analysis of Chordate Medical after Q2: “A step closer to fulfilling the market plan”

  • Uncategorized

    Biostock interview: “Promising results in Chordate’s follow-up study”

  • Uncategorized

    Chordate reports conclusions from first data monitoring of the ongoing long term open study on chronic migraine: PM010

  • Uncategorized

    Biostock interview: CEO Anders Weilandt on the Q2 report

1 2 3 4 5 … 18

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

Press releases

Chordate Medical terminates the liquidity provider agreement for the preference share

7 May 2025

Change of Certified Adviser (CA) to Bergs Securities

1 May 2025

Notice to the Annual General Meeting in Chordate Medical Holding AB (publ)

15 April 2025

Chordate Medical AB

Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31

Delivery: Hanstavägen 31, 164 53 Kista

Privacy policy

Twitter
Manage Cookie Consent
We use cookies on our website to provide you with the most relevant experience and personalize ads by remembering your preferences on repeat visits. By clicking "Accept all" you agree to the use of all cookies. You can also visit "Cookie Settings" to provide controlled consent.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}